XNASPMVP
Market cap75mUSD
Jan 10, Last price
1.46USD
1D
-3.31%
1Q
-2.01%
IPO
-95.97%
Name
PMV Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
8.98%
Rev. gr., 5y
%
Revenues
0k
Net income
-69m
L-5.94%
CFO
-56m
L-12.71%
Earnings
Feb 26, 2025
Profile
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | ||||||
Cost of revenue | 81,389 | 77,690 | ||||
Unusual Expense (Income) | ||||||
NOPBT | (81,389) | (77,690) | ||||
NOPBT Margin | ||||||
Operating Taxes | 2 | (9) | ||||
Tax Rate | ||||||
NOPAT | (81,391) | (77,681) | ||||
Net income | (68,960) -5.94% | (73,317) 26.75% | ||||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | 35,121 | 958 | ||||
BB yield | -23.60% | -0.24% | ||||
| Debt | ||||||
Debt current | 1,704 | 528 | ||||
Long-term debt | 25,720 | 27,424 | ||||
Deferred revenue | ||||||
Other long-term liabilities | ||||||
Net debt | (201,138) | (215,597) | ||||
| Cash flow | ||||||
Cash from operating activities | (55,657) | (63,760) | ||||
CAPEX | (962) | (7,984) | ||||
Cash from investing activities | (50,545) | (1,368) | ||||
Cash from financing activities | 35,577 | 958 | ||||
FCF | (79,945) | (85,025) | ||||
| Balance | ||||||
Cash | 203,057 | 241,054 | ||||
Long term investments | 25,505 | 2,495 | ||||
Excess cash | 228,562 | 243,549 | ||||
Stockholders' equity | (309,779) | (241,488) | ||||
Invested Capital | 549,514 | 501,492 | ||||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 48,015 | 45,595 | ||||
Price | 3.10 -64.37% | 8.70 -62.34% | ||||
Market cap | 148,845 -62.48% | 396,675 -61.96% | ||||
EV | (52,293) | 181,078 | ||||
EBITDA | (80,132) | (77,375) | ||||
EV/EBITDA | 0.65 | |||||
Interest | 4,029 | |||||
Interest/NOPBT | ||||||